Sharon Townson - May 28, 2024 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Scientific Officer
Signature
/s/ Phil Nickson, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
May 28, 2024
Transactions value $
$0
Form type
3
Date filed
6/5/2024, 04:05 PM
Previous filing
Jan 4, 2023
Next filing
Jun 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLUE Stock Option (Right to Buy) May 28, 2024 Common Stock 75K $1.13 Direct F1
holding GLUE Stock Option (Right to Buy) May 28, 2024 Common Stock 215K $6.14 Direct F2
holding GLUE Stock Option (Right to Buy) May 28, 2024 Common Stock 70K $13.41 Direct F3
holding GLUE Stock Option (Right to Buy) May 28, 2024 Common Stock 78.6K $7.78 Direct F4
holding GLUE Stock Option (Right to Buy) May 28, 2024 Common Stock 79K $5.71 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option vested and became exercisable on July 20, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of this option vested and became exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3 25% of this option vested and became exercisable on March 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F4 25% of this option vested and became exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney